Dr. Reddy’s Laboratories has reported three observations from the United States Food and Drug Administration (USFDA) following a Pre-Approval Inspection (PAI) at its FTO-9 manufacturing facility in Visakhapatnam, Andhra Pradesh. The inspection took place over two days, from October 8 to 9, 2026, according to the company’s regulatory filing.

 

The USFDA issued a Form 483 listing three inspectional observations. Such observations identify conditions that inspectors believe may indicate potential violations of regulatory requirements. They are not, by themselves, a final determination of non-compliance or an automatic ban on manufacturing.

Dr. Reddy’s Laboratories stated that it would address all three observations within the stipulated timeline. However, the company has not publicly disclosed the specific findings or the corrective measures planned in response. The observations’ potential impact on the facility’s operations has also not been detailed.

The development highlights the regulatory scrutiny faced by pharmaceutical manufacturing facilities supplying medicines to international markets. Further updates will depend on the company’s response and any subsequent regulatory action.